Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Sino Biopharmaceutical (SBMFF) had Revenue of $3.43B for the most recently reported fiscal year, ending 2020-12-31.

Quarterly Annual

Figures for fiscal year ending 2020-12-31

Income Statement Financials
Revenue	$3.43B
Net Income	$401.53M
Cost of Goods Sold	$750.92M
Gross Profit	$2.68B
Operating Expenses	$2.65B
Operating Income	$773.71M
Non-Operating Income/Expense	$-47.32M
Pre-Tax Income	$726.39M
Normalized Pre-Tax Income	$726.86M
Income after Taxes	$628.96M
Income from Continuous Operations	$628.96M
Consolidated Net Income/Loss	$628.96M
Normalized Income after Taxes	$629.49M
EBIT	$773.71M
EBITDA	$1.00B
Weighted-Average Shares Outstanding (Basic)	18.80B
Weighted-Average Shares Outstanding (Diluted)	18.80B
Earnings per Share (EPS) (Basic)	$0.02
Earnings per Share (EPS) (Diluted)	$0.02
Balance Sheet Financials
Current Assets	$3.30B
Property, Plant, and Equipment	$995.50M
Long-Term Assets	$3.54B
Total Assets	$6.84B
Current Liabilities	$1.59B
Long-Term Debt	$1.86B
Long-Term Liabilities	$2.01B
Total Liabilities	$3.59B
Common Equity	$3.25B
Tangible Shareholders Equity	$3.10B
Shareholders Equity	$3.25B
Common Shares Outstanding	18.86B
Cash Flow Statement Financials
Cash Flow from Operating Activities	$771.64M
Cash Flow from Investing Activities	$-1.14B
Cash Flow from Financial Activities	$323.59M
Beginning Cash	$1.54B
End Cash	$1.54B
Increase/Decrease in Cash	$-1.02M
Stock-Based Compensation	--
Common Stock Dividends Paid	$-393.34M
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.08
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.36
Debt to Equity Ratio	0.64
Gross Margin	78.08%
Operating Margin	22.58%
EBIT Margin	22.58%
EBITDA Margin	29.26%
Pre-Tax Profit Margin	21.20%
Profit Margin	11.72%
Free Cash Flow	$579.92M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.50
Inventory Turnover	2.76
Receiveable Turnover	8.11
Days Sales in Receivables	44.98
Return on Equity	19.36%
Return on Tangible Equity	20.28%
Return on Assets	9.19%
Return on Investments	12.32%
Book Value Per Share	$0.17
Free Cash Flow per Share	$0.03
Operating Cash Flow per Share	$0.04

Data from Zacks Investment Research, Inc.